Others

Glenmark Pharmaceuticals Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

| Updated on July 26, 2018 Published on July 26, 2018

Sub: Glenmark Pharmaceuticals Announces Encouraging Phase 1 Results Supporting Biosimilarity Criteria for GBR 310 Compared to the Reference Product Omalizumab

Pdf Link: Glenmark Pharmaceuticals Ltd. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Source : BSE - www.bseindia.com

Published on July 26, 2018
This article is closed for comments.
Please Email the Editor